Last Week in Weed November 9–15, 2026 | Testing Rules and Margin Pressure

NOVEMBER 16, 2026 EDITION · WEEK IN REVIEW NOVEMBER 9–15

A failed laboratory test and a falling margin each demand an explanation that a headline number cannot provide. During the week of Nov. 9–15, Massachusetts regulators advanced changes to how cannabis products are tested and labeled, while earnings from Charlotte’s Web and MariMed exposed the work behind their financial results. The developments put compliance, product access and the cost of growth at the center of the industry’s latest reporting.

Key Points

  • Massachusetts advanced draft testing requirements, including retesting failures and identifying remediation on labels.
  • Charlotte’s Web reported lower revenue alongside a narrower operating loss.
  • MariMed posted record quarterly revenue while its GAAP net loss widened year over year.
In This Article

Massachusetts Advances a Broader Testing Framework

Massachusetts’ Cannabis Control Commission advanced draft testing regulations at its Nov. 12 meeting, addressing the timing of compliance testing, the handling of failed results and the information consumers receive about a product.

The policy decisions include testing before business-to-business or consumer sales, targeted microbial testing for specified organisms, and automatic retesting of failures to distinguish laboratory error from genuine noncompliance. Product labels would also identify sanitization or remediation.

The commission expected an initial approval of the draft in December, followed by a broader public comment process beginning in January. It described implementation six months after promulgation, which was tentatively scheduled for April 2027.

The rules remain in development. Operators and laboratories will need to follow the eventual text and effective dates as the commission works through the process. The proposal connects testing procedures with the records and labels that accompany products through the supply chain.

Massachusetts Cannabis Control Commission, Nov. 12

Charlotte’s Web Cuts Losses as Revenue Falls

Charlotte’s Web reported third-quarter revenue of $9.4 million on Nov. 12, down 18.3% from $11.5 million a year earlier. The company attributed the decline principally to California’s full-spectrum hemp restrictions, reduced online discounting and other changes in its product range and demand.

Operating loss narrowed to $3.7 million from $5.3 million. Selling, general and administrative expenses declined to $8.1 million from $9.7 million, while gross profit was $4.4 million, compared with $4.5 million.

The figures show a business reducing costs and preserving much of its gross profit while bringing in less revenue. The company said it had reintroduced broad-spectrum products in California and was seeing sales begin to recover there.

The report makes product formulation and state-level access central to the company’s operating story. Its improved loss figures sit alongside continuing pressure on sales, leaving the return to sustained growth as a separate challenge.

Charlotte’s Web quarterly results, Nov. 12

MariMed’s Sales Growth Meets Continuing Margin Pressure

MariMed reported record quarterly revenue of $44.2 million on Nov. 11, an 8.5% increase from the same period in 2025. Wholesale and retail sales both grew, and the company said its branded products reached 721 stores during the quarter.

GAAP net loss widened to $3.5 million from $2.9 million a year earlier. Adjusted EBITDA, a non-GAAP measure, was $4.7 million, below the year-earlier $5.1 million, although it improved from the previous quarter. GAAP gross margin declined to 39% from 40%.

The company attributed pressure on its non-GAAP gross margin to continued wholesale price compression. It also reported a quarter-end cash position of approximately $10.4 million.

Those results illustrate how additional sales can coexist with pressure on earnings. MariMed’s quarterly improvement and annual comparisons tell different parts of the story, making the reporting period and the distinction between GAAP and adjusted measures essential to reading the release.

MariMed earnings release filed with the SEC, Nov. 11

Frequently Asked Questions

Have Massachusetts’ new testing rules taken effect?

No. The commission advanced draft regulations and outlined additional votes and public comment before implementation.

Is adjusted EBITDA equivalent to net income?

No. It excludes specified expenses and is a non-GAAP measure. MariMed reported positive adjusted EBITDA alongside a GAAP net loss.

Leave a Reply

Your email address will not be published. Required fields are marked *